Fresh analysis suggests that individuals who come off blockbuster GLP-1 drugs like semaglutide or tirzepatide can put back on reduced body mass far faster than those who halt traditional lifestyle programs.
Research printed in a leading health publication demonstrates that while overweight individuals frequently drop about a fifth of their body weight while on the medication, the weight comes back at an average rate of 0.8 kg per month once they quit.
"Individuals buying such medications must be cognizant of the potential of fast weight regain when the treatment concludes," stated lead investigator Dr. Susan Jebb.
That rate of recovery means a reversion to starting weight in about a year and a half.
Comparing Treatments
The study, which reviewed 37 of studies involving thousands of patients, contrasted the results of these new drugs with conventional dieting.
Researchers point out that people who shed pounds through lifestyle changes alone usually see a more gradual creep back—perhaps 100 grams monthly—once they finish.
The Reason for the Rapid Regain
Nutrition scientists believe the mechanism of the injections accounts for the accelerated rebound.
The injections imitate a natural hormone called glucagon-like peptide-1, which moderates hunger.
"Sustained high doses of GLP-1 concentrations far above than normal could lead to the body to produce less of its own natural hormone, and may also diminish responsiveness to its effects," explained Dr. Adam Collins, a nutrition expert.
"Stopping of this medication results in appetite is uncontrolled, making overeating much more probable."
A Lifelong Issue?
The NHS advise the injections for people with weight-linked health risks, alongside recommended lifestyle changes.
Professionals say that, considering the likelihood of weight regain, the treatment might need to be life-long.
This view is echoed by drug manufacturers, who say that the findings "emphasize the chronic character of obesity," comparing it to managing diseases like high blood pressure.
Patient Testimonies
People who have stopped the medication report a intense return of cravings.
"I experienced something activating and I was suddenly ravenous," said a patient.
The struggle is exacerbated if individuals have not developed lasting dietary or behavioural modifications during therapy.
Significant Use
Recent estimates suggest that a significant number of adults in the UK have used weight-loss jabs in the past year, with interest remaining high.
- Use is greater among females compared to males.
- The 40s and 50s demographic shows the greatest level of interest.
- A large proportion access the medications through private prescriptions rather than public health services.
In conclusion, clinicians emphasize that while the jabs are potent agents for shedding pounds, they are not a magic fix and long-term success likely depends on integrated lifestyle support.
